Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onabotulinum toxin A - Allergan

Drug Profile

Onabotulinum toxin A - Allergan

Alternative Names: Botox; Botulinum toxin A injectable-Allergan; GSK 1358820; Vistabel; Vistabex

Latest Information Update: 12 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Developer Allergan; GlaxoSmithKline; Johns Hopkins University; Temple University; University of Illinois at Chicago; Wake Forest University School of Medicine
  • Class Analgesics; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity; Torticollis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dysphonia; Facial wrinkles; Glabellar lines; Hyperhidrosis; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
  • Registered Equinus foot deformity
  • Phase III Muscle pain; Raynaud's disease
  • Phase II Carpal tunnel syndrome; Gastrointestinal disorders; Herpes labialis; Hypertrophy; Major depressive disorder; Musculoskeletal pain; Pain; Premature ejaculation
  • Phase I/II Pruritus
  • No development reported Benign prostatic hyperplasia
  • Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome

Most Recent Events

  • 20 Dec 2018 GlaxoSmithKline completes a phase III trial in Neurogenic bladder in Japan (IM) (NCT02849418)
  • 12 Nov 2018 GlaxoSmithKline completes a phase III trial in Overactive bladder in Japan (IM) (NCT02820844)
  • 11 Oct 2018 Allergan completes a phase III trial in Neurogenic bladder (In children, In adolescents) in USA, Belgium, Czech Republic, Austria, Italy, Germany, Poland, Canada, France and Turkey (IM) (NCT01852045)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top